Spectrum Pharma (SPPI) Misses Q1 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Spectrum Pharma (SPPI) Misses Q1 EPS by 9c

Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update

May 2, 2017 4:02 PM EDT

ROLONTIS (eflapegrastim): Phase 3 ADVANCE Pivotal study: Number of evaluable patients reduced to 400 from 580, per an amended Special Protocol Assessment (SPA) received from the FDA. ADVANCE study is 75% enrolled and the Company expects to complete enrollment in the second half of this year. To strengthen the regulatory package in the U.S. and Europe, the Company has initiated an international 218-patient RECOVER study and first patient enrollment is imminent. The Company continues to expect to file a BLA next year.... More